Stock Chart

CHRS

$1.16 0.00%
Score: 68.5 HOLD
Pro
Screener
Vol: 0.87x (vs SPY: 0.9x | vs QQQ: 0.8x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Bear Pennant weak / forming — below our quality gate quality 58/100
A Bear Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About CHRS - Coherus Oncology, Inc. Common Stock

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio …

Key Statistics

Market Cap $179M

More CHRS Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This CHRS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track CHRS's price movements with trendlines, gamma walls, and key support/resistance levels.